메뉴 건너뛰기




Volumn 63, Issue 6, 2016, Pages 730-734

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence

Author keywords

antibodies; epidemiology; risk factors; serology; toxin A

Indexed keywords

ACTOXUMAB; BEZLOTOXUMAB; IMMUNOGLOBULIN G; METRONIDAZOLE; PLACEBO; VANCOMYCIN; BACTERIAL PROTEIN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

EID: 84995400149     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw364     Document Type: Article
Times cited : (59)

References (29)
  • 1
    • 84923775846 scopus 로고    scopus 로고
    • Burden of Clostridium difficile infection in the United States
    • Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825-34.
    • (2015) N Engl J Med , vol.372 , pp. 825-834
    • Lessa, F.C.1    Mu, Y.2    Bamberg, W.M.3
  • 2
    • 79551527297 scopus 로고    scopus 로고
    • Fidaxomicin versus vancomycin for Clostridium difficile infection
    • Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
    • (2011) N Engl J Med , vol.364 , pp. 422-431
    • Louie, T.J.1    Miller, M.A.2    Mullane, K.M.3
  • 3
    • 19344363493 scopus 로고    scopus 로고
    • Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec Canada
    • Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-7.
    • (2005) Clin Infect Dis , vol.40 , pp. 1591-1597
    • Pepin, J.1    Alary, M.E.2    Valiquette, L.3
  • 4
    • 20444486921 scopus 로고    scopus 로고
    • Treatment of recurrent Clostridium difficile-associated disease
    • Surawicz CM. Treatment of recurrent Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2004; 1:32-8.
    • (2004) Nat Clin Pract Gastroenterol Hepatol , vol.1 , pp. 32-38
    • Surawicz, C.M.1
  • 6
    • 84953345711 scopus 로고    scopus 로고
    • Fecal microbiota transplantation for the treatment of Clostridium difficile infection
    • Rao K, Safdar N. Fecal microbiota transplantation for the treatment of Clostridium difficile infection. J Hosp Med 2015; 11:56-61.
    • (2015) J Hosp Med , vol.11 , pp. 56-61
    • Rao, K.1    Safdar, N.2
  • 7
    • 35348991541 scopus 로고    scopus 로고
    • Changing epidemiology of Clostridium difficile-associated disease in children
    • Benson L, Song X, Campos J, Singh N. Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 2007; 28:1233-5.
    • (2007) Infect Control Hosp Epidemiol , vol.28 , pp. 1233-1235
    • Benson, L.1    Song, X.2    Campos, J.3    Singh, N.4
  • 8
    • 41649114003 scopus 로고    scopus 로고
    • Surveillance for community-associated Clostridium difficile-Connecticut, 2006
    • Centers for Disease Control
    • Centers for Disease Control. Surveillance for community-associated Clostridium difficile-Connecticut, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:340-3.
    • (2008) MMWR Morb Mortal Wkly Rep , vol.57 , pp. 340-343
  • 9
    • 77957882527 scopus 로고    scopus 로고
    • Multicenter study of Clostridium difficile infection rates from 2000 to 2006
    • Dubberke ER, Butler AM, Yokoe DS, et al. Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infect Control Hosp Epidemiol 2010; 31:1030-7.
    • (2010) Infect Control Hosp Epidemiol , vol.31 , pp. 1030-1037
    • Dubberke, E.R.1    Butler, A.M.2    Yokoe, D.S.3
  • 11
    • 84867484557 scopus 로고    scopus 로고
    • Burden of Clostridium difficile infection in longterm care facilities in Monroe County New York
    • Pawar D, Tsay R, Nelson DS, et al. Burden of Clostridium difficile infection in longterm care facilities in Monroe County, New York. Infect Control Hosp Epidemiol 2012; 33:1107-12.
    • (2012) Infect Control Hosp Epidemiol , vol.33 , pp. 1107-1112
    • Pawar, D.1    Tsay, R.2    Nelson, D.S.3
  • 12
    • 79958761012 scopus 로고    scopus 로고
    • Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals
    • Zilberberg MD, Tabak YP, Sievert DM, et al. Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals. Infect Control Hosp Epidemiol 2011; 32:649-55.
    • (2011) Infect Control Hosp Epidemiol , vol.32 , pp. 649-655
    • Zilberberg, M.D.1    Tabak, Y.P.2    Sievert, D.M.3
  • 13
    • 56249107224 scopus 로고    scopus 로고
    • Meta-analysis to assess risk factors for recurrent Clostridium difficile infection
    • Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008; 70:298-304.
    • (2008) J Hosp Infect , vol.70 , pp. 298-304
    • Garey, K.W.1    Sethi, S.2    Yadav, Y.3    Dupont, H.L.4
  • 14
    • 74249096590 scopus 로고    scopus 로고
    • Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)
    • Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28:965-9.
    • (2010) Vaccine , vol.28 , pp. 965-969
    • Leav, B.A.1    Blair, B.2    Leney, M.3
  • 15
    • 74849098405 scopus 로고    scopus 로고
    • Treatment with monoclonal antibodies against Clostridium difficile toxins
    • Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205.
    • (2010) N Engl J Med , vol.362 , pp. 197-205
    • Lowy, I.1    Molrine, D.C.2    Leav, B.A.3
  • 16
    • 0028972348 scopus 로고
    • Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime
    • Impallomeni M, Galletly NP, Wort SJ, Starr JM, Rogers TR. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ 1995; 311:1345-6.
    • (1995) BMJ , vol.311 , pp. 1345-1346
    • Impallomeni, M.1    Galletly, N.P.2    Wort, S.J.3    Starr, J.M.4    Rogers, T.R.5
  • 17
    • 84899796356 scopus 로고    scopus 로고
    • Risk estimation for recurrent Clostridium difficile infection based on clinical factors
    • D'Agostino RB Sr, Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin Infect Dis 2014; 58:1386-93.
    • (2014) Clin Infect Dis , vol.58 , pp. 1386-1393
    • D'Agostino, Sr.R.B.1    Collins, S.H.2    Pencina, K.M.3    Kean, Y.4    Gorbach, S.5
  • 18
    • 79952588451 scopus 로고    scopus 로고
    • Development and validation of a Clostridium difficile infection risk prediction model
    • Dubberke ER, Yan Y, Reske KA, et al. Development and validation of a Clostridium difficile infection risk prediction model. Infect Control Hosp Epidemiol 2011; 32:360-6.
    • (2011) Infect Control Hosp Epidemiol , vol.32 , pp. 360-366
    • Dubberke, E.R.1    Yan, Y.2    Reske, K.A.3
  • 19
    • 84863651274 scopus 로고    scopus 로고
    • Predictors of first recurrence of Clostridium difficile infection: Implications for initial management
    • Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012; 55: S77-87.
    • (2012) Clin Infect Dis , vol.55 , pp. S77-S87
    • Eyre, D.W.1    Walker, A.S.2    Wyllie, D.3
  • 20
    • 84903755337 scopus 로고    scopus 로고
    • Development and validation of a recurrent Clostridium difficile risk-prediction model
    • Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER. Development and validation of a recurrent Clostridium difficile risk-prediction model. J Hosp Med 2014; 9:418-23.
    • (2014) J Hosp Med , vol.9 , pp. 418-423
    • Zilberberg, M.D.1    Reske, K.2    Olsen, M.3    Yan, Y.4    Dubberke, E.R.5
  • 21
    • 0035915688 scopus 로고    scopus 로고
    • Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
    • Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189-93.
    • (2001) Lancet , vol.357 , pp. 189-193
    • Kyne, L.1    Warny, M.2    Qamar, A.3    Kelly, C.P.4
  • 22
    • 0036467063 scopus 로고    scopus 로고
    • Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile
    • Kyne L, Hamel MB, Polavaram R, Kelly CNP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34:346-53.
    • (2002) Clin Infect Dis , vol.34 , pp. 346-353
    • Kyne, L.1    Hamel, M.B.2    Polavaram, R.3    Kelly, C.N.P.4
  • 23
    • 0028089161 scopus 로고
    • Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection
    • Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62:384-9.
    • (1994) Infect Immun , vol.62 , pp. 384-389
    • Warny, M.1    Vaerman, J.P.2    Avesani, V.3    Delmee, M.4
  • 25
    • 67349114409 scopus 로고    scopus 로고
    • Toxin B is essential for virulence of Clostridium difficile
    • Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176-9.
    • (2009) Nature , vol.458 , pp. 1176-1179
    • Lyras, D.1    O'Connor, J.R.2    Howarth, P.M.3
  • 26
    • 80455173556 scopus 로고    scopus 로고
    • Host and pathogen factors for Clostridium difficile infection and colonization
    • Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365:1693-703.
    • (2011) N Engl J Med , vol.365 , pp. 1693-1703
    • Loo, V.G.1    Bourgault, A.M.2    Poirier, L.3
  • 27
    • 84871775506 scopus 로고    scopus 로고
    • Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease
    • Steele J, Mukherjee J, Parry N, Tzipori S. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 2013; 207:323-30.
    • (2013) J Infect Dis , vol.207 , pp. 323-330
    • Steele, J.1    Mukherjee, J.2    Parry, N.3    Tzipori, S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.